BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
March 02 2023 - 7:30AM
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the
“Company”) (NASDAQ:BRTX), a clinical stage company focused on stem
cell-based therapies, today announced that the United States Patent
and Trademark Office has issued a notice of allowance for a patent
application related to the Company’s metabolic ThermoStem® program.
The notice of allowance was issued on February 24, 2023.
This will be the third patent granted under this
particular family of intellectual property, claims granted under
the new patent cover implantable three-dimensional scaffolds and
brown adipocytes that have been derived from human brown
adipose-derived stem cells. Therapeutic benefits of using brown
adipose have been demonstrated in various models and may provide a
valuable therapeutic tool for treating a range of metabolic
disorders. In addition, BioRestorative is evaluating the use of
this technology to target indications outside of metabolic
disorders.
“This is the second notice of allowance we have
received regarding our ThermoStem® program within 2023. This notice
of allowance is very meaningful as it provides the Company with
further protection and strengthens our technology as we develop and
expand into the clinic. Additionally, it enhances our ability to
engage with the strategic community on collaborative and partnering
opportunities” said Lance Alstodt, the Company’s CEO.
About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have commenced a
Phase 2 clinical trial using BRTX-100 to treat chronic
lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and
diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024